ResMed Inc. (RMD) is a publicly traded Healthcare sector company. As of May 21, 2026, RMD trades at $210.64 with a market cap of $29.61B and a P/E ratio of 20.24. RMD moved +1.11% today. Year to date, RMD is -14.47%; over the trailing twelve months it is -15.43%. Its 52-week range spans $198.61 to $293.81. Analyst consensus is buy with an average price target of $264.56. Rallies surfaces RMD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ResMed slides after Q3 beat as investors eye costs and post-earnings positioning: ResMed shares fell after reporting fiscal Q3 2026 results, despite beating expectations on adjusted EPS and delivering double-digit revenue growth. The pullback appears driven by investors taking profits and focusing on expense growth and other below-the-surface items in the quarter.
| Metric | Value |
|---|---|
| Price | $210.64 |
| Market Cap | $29.61B |
| P/E Ratio | 20.24 |
| EPS | $10.41 |
| Dividend Yield | 0.60% |
| 52-Week High | $293.81 |
| 52-Week Low | $198.61 |
| Volume | 146 |
| Avg Volume | 0 |
| Revenue (TTM) | $5.54B |
| Net Income | $1.52B |
| Gross Margin | 61.59% |
13 analysts cover RMD: 0 strong buy, 8 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $264.56.